Merck Advances Zilovertamab Vedotin Trials in B-Cell Malignancies

Merck is actively engaged in research with zilovertamab vedotin for B-cell malignancies, launching the waveLINE clinical trial program. This program includes a Phase 2/3 study for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and a Phase 3 study for treatment-naïve DLBCL patients.

Merck is dedicated to advancing treatments for hematologic disorders, focusing on innovative mechanisms to meet unmet patient needs. Their extensive clinical development program explores investigational medicines both as standalone treatments and in combination with other therapies.

As a leader in oncology, Merck is committed to discovering new cancer treatments. Their diverse pipeline includes over 25 novel mechanisms across more than 30 tumor types. Merck aims to address barriers in clinical trial participation and improve access to cancer care.

Merck, known as MSD outside the U.S. and Canada, has been a leader in biopharmaceutical research for over 130 years. Their mission is to deliver innovative health solutions globally, fostering a diverse and inclusive workforce to ensure a sustainable and healthy future.

Merck's forward-looking statements are subject to risks and uncertainties, including regulatory approvals and market conditions. The company emphasizes that actual results may differ from forward-looking statements due to various factors, including industry competition, economic conditions, and regulatory challenges.